The present study evaluated the in vivo antitumor effects and toxicity of a new Ru (II) ) significantly reduced tumor volume and weight, induced oxidative stress in tumor tissue, reduced the respiration of tumor cells, and induced necrosis but did not induce apoptosis in the tumor. No clinical signs of toxicity or death were observed in tumor-bearing or healthy rats that were treated with RuC. These results suggest that RuC has antitumor activity through the modulation of oxidative stress and impairment of oxidative phosphorylation, thus promoting Walker-256 cell death without causing systemic toxicity. These effects make RuC a promising anticancer drug for clinical evaluation.
Introduction
The increasing incidence of neoplastic diseases shows that more effective chemotherapeutic agents with lower toxicity are needed to improve patients' well-being and adherence to treatment. Cisplatin (cisdiaminedichloroplatinum II) is a chemotherapeutic drug that is used to treat solid tumors of the ovaries, cervix, testis, lungs, head, and neck [1, 2] . However, cisplatin treatment is accompanied by adverse doselimiting effects, such as nephrotoxicity, ototoxicity, neurotoxicity, gastrointestinal toxicity, and bone marrow toxicity [3, 4] . Significant side effects and drug resistance limit the clinical applications of cisplatin and have stimulated the development of non-platinum metalbased therapies [5] [6] [7] . Based on the chemical structure of cisplatin, ruthenium (Ru)III complexes have been shown to have important antitumor properties in numerous in vitro and in vivo tumor models and lower systemic toxicity than platinum(II) compounds [8, 9] .
The Ru(III) complexes NAMI-A ([Him][trans-RuCl4(DMSO)(im)], im = imidazole), KP1019 ([Hind]-[trans-(RuCl4[ind]
2), ind = indazole), and its Na + analogue KP1339 have been shown to have therapeutic effects that are similar to cisplatin but are more selective for tumor cells [10] [11] [12] . The biological targets of NAMI-A and KP1019 have not yet been thoroughly elucidated. Both of these compounds are able to target DNA and proteins, suggesting multiple pathways or pathways that are different from those of cisplatin [13] [14] [15] . NAMI-A [16] is selective for metastatic cells, whereas KP1019 [17] acts only on primary tumors. Both of these compounds exhibit excellent activity against colorectal tumor cells [18] . Previous studies suggested that both Ru(III) complexes act as pro-drugs. In biological media, their actions against tumor cells are activated by the reduction to Ru(II) by biological reducing agents, such as glutathione, ascorbic acid, cysteine, and cytochrome c [19] [20] [21] [22] [23] . Ru(II) interacts with DNA, proteins, and other biomolecules to disturb the function of tumor cells [24] . Electrochemical experiments have shown that this reduction is favored in tumor tissue compared with healthy tissue because of the low oxygen concentration (i.e., hypoxia) and acid pH that are caused by the intense production of lactic acid in solid tumors [25] [26] [27] . Cancer cells must rewire cellular metabolism to satisfy the demands of tumor cell growth and proliferation. Most tumor cells rely on adenosine triphosphate synthesis by glycolysis rather than oxidative phosphorylation, a phenomenon known as the Warburg effect [28] . This process was initially attributed to mitochondrial dysfunction, but this mechanism is now being reevaluated because of the important role of this organelle in cancer. In fact, in cancerous states, anaplerotic and cataplerotic mitochondrial reactions work together to provide sufficient biosynthetic precursors to sustain cell growth and proliferation. Thus, in contrast to Warburg's first observations, the maintenance of functional mitochondria appears to be a key process for cancer cell survival and proliferation [29, 30] . Consequently, intense mitochondrial energy metabolism becomes an important source of reactive oxygen species (ROS) [31] , such as superoxide anion (O 2
•-) [32, 33] , nitric oxide (NO • ) [34] , protonated superoxide (HO 2 • ), hydrogen peroxide (H 2 O 2 ), peroxynitrite (ONOO -) [35, 36] and hydroxyl (HO • ), all of which are extremely reactive. Cisplatin acts in tumor cells through the production of ROS. Similarly, the activation of Ru(II) by the oxidation of Ru(III) in tumor cells plays a crucial role in the oxidative process and electron transport in the respiratory chain. These findings encouraged us to study the antitumor activity, oxidative balance, mitochondrial activity, and toxicity of a novel Ru(II) compound:
which L-L is 1,10-phenanthroline (phen) and L is imidazole (ImH). Hereinafter, this compound is referred to as RuphenImH or RuC [37] . We performed in vivo and in vitro studies using a Walker-256 carcinosarcoma cell model. This tumor grows fast, induces cachexia and oxidative stress, and has high metabolic demands. 1) . The removal of solvent and addition of hexafluorophosphate induced precipitation of the complex as a dark red powder. The composition and molecular structure of the complex was confirmed by CHN analyses and NMR spectroscopy as described by Cardoso et al. [37] . ) (B), tumor weight (g) (C), and weight gain (D) in healthy (baseline) and tumor-bearing rats that were treated with RuC, cisplatin, and vehicle (control) for 13 days. The data are expressed as mean ± SEM. The statistical analyses were performed using two-way (B) or one-way (C, D) ANOVA followed by the Bonferroni test.
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b, * , # Significant difference from baseline, control, and cisplatin groups, respectively (one, two, and three symbols refer to p < 0.05, p < 0.01, and p < 0.001, respectively).
Methods
Animal handling and ethical issues
Male Wistar rats, weighing 180-220 g, were obtained from the Central Animal House of the Federal University of Paraná (Curitiba, Brazil). The animals were housed in plastic cages (41 cm × 32 cm × 16.5 cm) with four rats per cage and food (Nuvital®) and water available ad libitum. They were maintained in a temperature-controlled room (22°C ± 2°C) under a 12 h/12 h light/dark cycle (lights on at 7 A.M.). All of the experimental protocols that involved animals were performed in accordance with the recommendations of Brazilian laws for the scientific management of animals and the Principles of Laboratory Animal Care (NIH Publication no. 85-23, revised 1985) . The Institutional Animal Ethics Committee of the Federal University of Paraná revised and approved all of the procedures in the present study (certificate no. 822).
Handling and inoculation of Walker-256 tumor cells
The maintenance of Walker-256 cells in Wistar male rats was performed by weekly passages (4 or 5) through intraperitoneal (i.p.) inoculation according to Vicentino et al. [38] . After 5-7 days, the animals developed ascites. The rats were then euthanized, and ascitic fluid was collected and centrifuged at 1126×g for 10 min at 4°C. The supernatant was discarded, and the precipitate was resuspended in 1 ml of phosphate-buffered saline (PBS; 16.5 mM phosphate, 137 mM NaCl, and 2.7 mM KCl). The viability of tumor cells was assessed by the Trypan blue exclusion method in a Neubauer chamber. Approximately 10 7 Walker-256 cells were injected subcutaneously in the right pelvic limb in each rat for preclinical trials using the solid tumor model.
Experimental design and sample collection
Treatment began 1 day after the subcutaneous inoculation of tumor cells and continued for 13 days. Ruthenium complex was dissolved in PBS that contained 2% Tween 80. Cisplatin was dissolved in PBS. Both compounds were used in a maximum volume of 0.3 ml per rat. The selected doses for RuC were 5 and 10 mg kg performed every 3 days to reduce toxicity. The control group received a similar volume of vehicle. For some of the parameters, a baseline group was added, which consisted of non-tumor-bearing rats that received vehicle during the experiment. The number of rats (n) in each group was 6-8. Following day 13 of treatment, all of the animals were anesthetized with an i.p. injection of 60 mg kg −1 ketamine (Quetamina, Vetnil, Louveira, Brazil) and 7.5 mg kg −1 xylazine (Kensol, König, Santana de Parnaíba, Brazil). Blood samples from the inferior cava vein were obtained for biochemical and hematological assays. The animals were euthanized, and the tumor, liver, lungs, kidneys, and spleen were removed and weighed, and tumor, liver and kidney tissues were stored at −80°C for further analyses.
Biophysical measurements
During treatment, the tumor volume was calculated by measuring its diameter using a pachymeter according to Mizuno et al. [39] :
where a is the smallest diameter, and b is the largest diameter (in centimeters). We also assessed the inhibitory effect, when appropriate, using the following formula:
where T is the average volume in the experimental group, and C is the average volume in the control group. The animals' body weight was daily checked. After recording the weight, we determined weight gain as the following:
where W end is the body weight on the day of euthanasia, minus the tumor weight.
Plasma biochemistry and hematological assays
Plasma samples were obtained after blood centrifugation at 3000×g for 10 min at 4°C. These samples were used to determine plasma urea, creatinine, alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT), aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), and alkaline phosphatase (AP) using commercial kits (Kovalent, Reagelabor, São Paulo, Brazil) and an automated device (Cobas Mira, Roche Diagnostics, Germany). Hematological parameters were investigated using whole blood and a BC2800-Vet automated device (Mindray, Shenzhen, China).
Tumor gene expression
Tumor samples were homogenized in TRIzol reagent (Life Technologies, Carlsbad, USA) to extract RNA. Complementary cDNA was prepared from 500 ng RNA in a 20 μl reaction volume that contained 0.5 mmol deoxyribonucleotide triphosphate, 1 µmol oligodT, 10 U RNasin (Promega, Madison, USA), and a high-capacity polymerase enzyme kit (Life Technologies). The negative control consisted of adding all of the products that were needed for cDNA synthesis except the reverse transcriptase. Quantitative polymerase chain reaction was performed using a Step One Plus thermocycler with the 1x Syber Green PCR Master Mix Kit (Applied Biosystems, Life Technologies). The primers were prepared (Invitrogen, São Paulo, Brazil) with the following sequences: internal control (600 nM) Gapdh (forward: 5′-AAG-GACCCCTTCATTGAC-3′; reverse: 5′-TCCACGACATACTCAC-3′) and the apoptotic markers (200 nM) Bcl-2 (forward: 5′-GACTGAGTACCTGAA-CCGGC-3′; reverse: 5′-AGTTCCACAAAGGCATCCAG-3′), Bax (forward: 5′-AAACTGGTGCTCAAGGCCC-3′; reverse: 5′-GGGTCGCGAAGTAGGA-AAGG-3′), p53 (forward: 5′-AGCGACTACAGTTAGGGGGTA-3′; reverse: 5′-ACAGTTATCCAGTCTTCAGGGG-3′), caspase 3 (forward: 5′-GGTATT-GAGA CAGACAGTGG-3′; reverse: 5′-CATGGGATCTGTTTCTTTGC-3′), Vegf (forward: 5′-AGAAACCCAATGAAGTGGTG-3′; reverse: 5′-ACTCCA-GGGCTTCATCATTG-3′), Cat (forward: 5′-TTCTACACTGAAGATGGTA-ACTG-3′; reverse: 5′-GAAAGTAACCTGATGGAGAGAC-3′), and Nrf2 (forward: 5′-ATGTCACCAGCTCAAGGGCACAGTGC-3′; reverse: 5′-CCATCCTCCCCGAACCTAGTT-3′). Relative expression levels were calculated as described previously [40] .
In vitro free radical-scavenging activity of RuC
The reactivity of RuC and cisplatin with the stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) was measured using an adaptation of the method of Chen et al. [41] . The system consisted of 250 μl of a methanolic solution of DPPH (1 mg in 25 ml), which was then combined with 750 μl of six ascending test solutions of each product (1-300 µg ml −1 ). The decrease in absorbance was measured after 5 min. A solution of the reducing agent ascorbic acid (50 µg ml −1 ) was used as the positive control, and distilled water was used as the negative control. Considering possible color shifts in the solutions that occur because of naturally occurring pigments in the test substances, we included measurements of the absorbance of each solution prior to the addition of DPPH, which were subtracted from the final values. Absorbance was measured at 517 nm using a microplate reader (BioTek Synergy HT, BioTek Instruments, Winooski, USA).
3.2.3.
In vivo oxidative stress parameter assays 3.2.3.1. Lipid peroxidation rate. The lipid peroxidation (LPO) rate was measured by the FOX-2 method [42] . This technique determines lipid hydroperoxide synthesis during peroxidation. Tumor, liver, and kidney samples were homogenized at 25,000 rotations per minute and then dissolved in methanol (1:2 ratio). They were then centrifuged at 5000×g for 5 min at 4°C. Absorbance of the supernatant was measured at 560 nm using a microplate reader. The results are expressed as nmol·mg protein −1 .
3.2.3.2.
Catalase, superoxide dismutase, and glutathione-S-transferase activity. For the biochemical analyses of these enzymes, liver, tumor, and kidney samples were homogenized in phosphate buffer, pH 6.5. Catalase (Cat) activity was measured according to Aebi [43] . The reaction was performed in a microplate reader and examined at 240 nm, and activity is expressed as nmol mg protein −1 . Superoxide dismutase (SOD) activity was measured as the ability of this enzyme to inhibit pyrogallol auto-oxidation according to the method of Gao et al. [44] . The reaction was performed in a 96-well microplate and examined at 440 nm. The amount of enzyme that inhibited the reaction by 50% (IC 50 ) was defined as one unit of SOD, and enzyme activity is expressed as Units of SOD mg protein −1 . The activity of glutathione-S-transferase (GST) was measured according to the method of Habig et al. [45] , which is based on the ability of this enzyme to conjugate the substrate 2,4-dinitrochlorobenzene (DNCB) with reduced glutathione, forming a thioether that can be measured as an increase in absorbance at 340 nm. Glutathione-S-transferase levels are expressed as nmol min −1 mg protein −1 .
Reduced glutathione levels. Reduced glutathione (GSH) levels
were measured according to the method of Sedlak and Lindsay [46] using tissue that was homogenized with trichloroacetic acid. After centrifugation at 13,750×g for 10 min at 4°C, the absorbance of the reaction with 5,5′-dithiobis-(2-nitrobenzoic acid) in methanol was measured at 415 nm in a microplate reader. The individual values were interpolated into a standard curve of GSH and are expressed as μg g tissue
.
Quantification of tissue proteins
The quantification of proteins in organs and tumor samples was performed according to the method of Bradford [47] . The reaction was examined at 595 nm in a microplate reader using bovine serum albumin as the protein standard in the concentration curve. The amount of protein was used to calculate the oxidative stress parameters (Cat, SOD, GST, and LPO).
Tumor and organ histology
Fragments from tumor, kidney, and liver tissues were fixed in buffered 10% formalin at room temperature. After fixation, the samples were dehydrated in ethanol, cleared with xylol, and embedded in paraffin. Thin sections (4 mm) were then processed for histology. Tissues were stained with hematoxylin and eosin, and the resulting slides were evaluated by optic microscopy in a blinded fashion. The following parameters were evaluated in tumor tissue: necrosis, tumor infiltration, and apoptosis. The following Ehrlich tumor classification was used [48] : 0 (lesions within < 5% of tissue), 1 (lesions within 5-25% of tissue), 2 (lesions within 26-50% of tissue), 3 (lesions within 51-75% of tissue), and 4 (lesions within > 75% of tissue). The livers and kidneys were checked for lymphocytic infiltrates, cell tumefaction, edema, necrosis, and cytological characteristics. The lesions were classified according to intensity: negative (−), mild (+), moderate (++), and pronounced (+++).
Oxygen uptake of Walker-256 ascitic cells
After four weekly passages of Walker-256 cells through i.p. inoculation [38] , Wistar rats were euthanized, and ascitic fluid was collected and centrifuged at 570 × g for 15 min at 4°C. The supernatant was discarded, and the precipitate was resuspended in 3.0 ml of 1.5 mmol L −1 NaCl and incubated for 2 min to lyse the erythrocytes.
Washing and lysis were performed until the complete removal of erythrocytes. The Walker-256 cells were resuspended in RPMI, and cell viability was assessed by the Trypan blue exclusion method in a Neubauer chamber. Cell respiration was then measured by high-resolution respirometry using an Oxygraph-2k device (Oroboros Instruments, Innsbruck, Austria) and two chambers at 37°C under gentle agitation. The oxygen uptake of 10 6 cells/chamber was monitored in RPMI immediately (time 0) and 10 min after incubation with RuC (10, 50, and 100 nmol −1 ) or cisplatin (5 and 10 µmol
). The concentrations were based on our previous experiments, in which the IC 50 values for cisplatin and RuC were 10 and 100 nmol −1 , respectively, within 48 h for HeLa and HepG2 cells (unpublished data). Oxygen consumption was determined in the different states of respiration as described previously [49] [50] [51] [52] [53] . The states of oxygen consumption were defined as the following: basal (oxygen consumption in the absence of inhibitors or uncouplers), leak (respiration in the presence of 2 µg ml −1 oligomycin, which results in the reentry of protons into the mitochondrial matrix and represents respiration that is not coupled to ATP synthesis), and uncoupled (oxygen consumption in the presence of 0.5 µmol −1 FCCP, which corresponds to the maximal respiratory capacity to restore the dissipated proton gradient due to the presence of the uncoupling agent). The oxygen flow in these states was corrected by subtracting non-mitochondrial respiration, which was obtained after the addition of rotenone (0.5 µmol ).
Statistical analysis
Mean differences were determined by one-way analysis of variance (ANOVA) followed by the Bonferroni or Tukey post hoc test or two-way ANOVA followed by the Bonferroni test when comparing tumor growth curves. The data are expressed as mean ± SEM. All of the analyses were performed using Prism 5.0 software (GraphPad, San Diego, USA). For all of the comparisons, values of p < 0.05 were considered statistically significant.
Results
Biophysical parameters
The tumor volume was measured daily beginning on day 5 (when it became palpable) until day 13. The groups that were treated with 5 and 10 mg kg −1 RuC, p.o., and 5 mg kg −1 RuC, i.p., did not differ from the control group (Fig. 1A) . The groups that were treated with 10 mg kg
RuC, i.p., and 2 mg kg −1 cisplatin, i.p., presented 72% and 91% reductions of tumor volume, respectively, compared with the control group (Fig. 1B) . Similarly, the 5 and 10 mg kg −1 RuC, i.p., and cisplatin groups presented significant 60%, 89%, and 91% reductions of tumor weight, respectively (Fig. 1C) . The cisplatin group exhibited significant weight loss during treatment, unlike the groups that received 5 mg kg −1 RuC, p.o., and 5 and 10 mg kg −1 RuC, i.p., which presented similar weight recovery as the basal group, which surpassed the weight gain of the control group (Fig. 1D) . The relative organ weight is presented as a percentage of body weight (Fig. 2) . The relative weight of the kidney ( Fig. 2A) decreased in animals that received cisplatin, similar to the 10 mg kg −1 RuC, p.o.,
group. The weight of the spleen (Fig. 2C ) was increased by~33% in most of the tumor groups, with the exception of the group that was treated with 10 mg kg −1 RuC, i.p. The weights of the liver (Fig. 2B) and lungs ( Fig. 2D) were not different among groups.
Plasma biochemistry and hematology
The presence of the tumor (control) caused blood alterations compared with baseline values, including an increase in plasma creatinine, decrease in ALT, decrease in AP, and decrease in the number of lymphocytes. Cisplatin treatment accentuated these alterations, increasing the levels of urea and creatinine, decreasing AP, and decreasing granulocyte and monocyte counts, indicating some degree of toxicity. RuC treatment normalized most of these hematological alterations, with only a slight decrease in granulocyte and lymphocyte counts in rats that were treated with 10 mg kg −1 RuC, i.p. (Table 1 ).
Tumor gene expression
As shown in Fig. 1 , the highest i.p. dose of RuC exerted a significant antitumor effect. Thus, we investigated the effects of the treatments on the expression of genes that are related to apoptosis, angiogenesis, and oxidative stress. We observed upregulation of the expression of p53 (Fig. 3A) , Bax (Fig. 3B), and caspase 3 (Fig. 3D) and no changes in the expression of Vegf (data not shown) in tumors from animals that were treated with cisplatin. RuC treatment did not alter the expression of nuclear factor E2-related (Nrf2; Fig. 3F ) or apoptosis-and angiogenesisrelated genes, but it reduced the expression of catalase (Cat) compared with the cisplatin group (Fig. 3E) .
In vitro free radical-scavenging activity
The antioxidant effect of RuC was evaluated in vitro, free from biological interference. Antioxidant activity was observed at all RuC concentrations (1-300 µg ml −1 ; Fig. 4A ), indicating activity that was similar to the positive control (ascorbic acid). Cisplatin had antioxidant properties only at the highest concentrations (Fig. 4B) . The data are expressed as mean ± SEM. The statistical analyses were performed using one-way ANOVA followed by the Bonferroni test. b, * , # Significant difference from baseline, control, and cisplatin groups, respectively (one, two, and three symbols refer to p < 0.05, p < 0.01, and p < 0.001, respectively). The data are expressed as mean ± SEM. The statistical analyses were performed using one-way ANOVA followed by the Bonferroni test. b, * , # Significant difference from baseline, control, and cisplatin groups, respectively (one, two, and three symbols refer to p < 0.05, p < 0.01, and p < 0.001, respectively). ). The data are expressed as mean ± SEM and were analyzed by one-way ANOVA followed by the Bonferroni test. *p < 0.05, and ***p < 0.001, compared with negative control.
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Fig. 3. Gene expression of p53 (A), Bax (B), Bcl-2 (C), caspase 3 (D), catalase (E),
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In vivo Oxidative Stress Parameters
We observed in vitro antioxidant effects of RuC. We then measured oxidative stress parameters in tumor, hepatic, and kidney tissues. RuC, mainly at the highest i.p. dose, induced significant changes in tumor tissue compared with the control group, reflected by decreases in SOD (−50%) and Cat (−45%) activity and increases in GSH (43%) and LPO (27%) levels (Fig. 5A,D,J,M) . The changes that were induced by cisplatin were less pronounced, in which it reduced SOD and Cat activities (Fig. 5A,D) and the LPO rate (Fig. 5M) . The presence of Walker-256 tumors also caused systemic alterations, reflected by oxidative stress parameters in the liver (Fig. 5B, E, H, K, N) and kidney (Fig. 5C,F,I,L,O) . The tumor elevated SOD activity, reduced Cat and GST activity, reduced GSH levels, and elevated LPO rates in both organs compared with the baseline group. These alterations were attenuated by RuC treatment but not cisplatin. RuC elevated GST activity and GSH and LPO levels in both organs and increased Cat activity in the kidneys. All of these parameters reached values that were similar to the baseline group.
Walker-256 tumor histology
Tumors in the control and RuC groups presented a high degree of necrosis and mononuclear infiltration, which were more intense (grade 4) with the dose of 10 mg kg -1 RuC. Lymphocytes and plasmocytes were the predominant infiltrated cells. These features were different from and cisplatin groups, respectively (one, two, and three symbols refer to p < 0.05, p < 0.01, and p < 0.001, respectively).
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cisplatin-treated rats, which presented a low degree of necrosis and cell infiltration in the tumors (grades 0 and 1, respectively). However, cell contraction, cytoplasmic eosinophilia, pycnosis, and cariorexis were observed, which are indicative of apoptosis (Fig. 6 ).
Walker-256 cell respiration
We observed effects of RuC on oxidative processes in vivo. We then evaluated the direct actions of RuC on the respiration of Walker-256 cells that were collected from ascitic tumors. This assay was performed using non-permeabilized cells in an attempt to approximate the experimental physiological conditions. Fig. 7 shows cell respiration immediately and 10 min after the addition of RuC and cisplatin. The rate of basal respiration (i.e., in the absence of inhibitors or uncouplers) was significantly decreased by both compounds and conditions. Cisplatin at the highest concentration (10 µM) inhibited respiration immediately (40% reduction) and after 10 min of incubation (53% reduction). RuC at 100 nM inhibited respiration by 56% and 47% under the same conditions, respectively. In the leak state (i.e., in the presence of oligomycin), no differences were observed immediately in incubation. After 10 min of incubation cisplatin (10 µmol ) inhibited respiration by 55% and 62%, respectively, compared with the control. In the presence of FCCP (uncoupled state), cisplatin and RuC also decreased oxygen flow similarly to the basal state (Fig. 7E, F) .
Toxicity parameters in healthy rats
Cisplatin is a cytotoxic drug [37] . We compared the toxicity of RuC and cisplatin by evaluating toxicological parameters in healthy (nontumor) rats that were treated for 13 days with 10 mg kg 1 RuC (i.p.) or 2 mg kg 1 cisplatin (i.p.), which exerted antitumor effects in Walker-256
tumor-bearing rats. The relative weights of the liver, spleen, and lung
were not significantly different among groups (Fig. 8A-C ). Significant weight loss (−141%) and an increase in kidney weight (55%) were observed in the group that was treated with 2 mg kg −1 cisplatin (i.p.) compared with the baseline group (Fig. 8E) . These results were confirmed by histological analysis of the kidney and liver ( Supplementary  Fig. 1S ). Only rats that were treated with cisplatin exhibited renal alterations (Fig. 8F) , reflected by slight to moderate tumefaction of the tubular epithelium, predominantly in the internal cortex and external medullar regions, and occasional pycnosis and cariorexis, both indicative of cell death. No such changes were observed in the group that was treated with 10 mg kg −1 RuC, i.p. (Fig. 8D, E) . These results suggest low toxicity of RuC, which is consistent with the data from tumorbearing rats (Table 1 , Fig. 1D , 2, 5-liver and kidney).
Discussion
The RuphenImH compound (RuC) exerted significant antitumor effects against Walker-256 carcinoma in vivo. We found that RuC inhibited tumor growth similarly to cisplatin ( Fig. 1) but had less toxicity and did not cause weight loss. Toxicity and weight loss are common side effects of cisplatin treatment. The effectiveness of cisplatin as an anticancer agent has stimulated the search for cytotoxic compounds that contain heavy metals other than platinum and have lower systemic toxicity and greater efficacy. Many ruthenium complexes have been studied as antineoplastic compounds because of their actions in the tumor microenvironment [7] , including cis-(Ru[1,10-phenanthroline] 2 [imidazole] 2 ) 2+ , which was used in vivo in the present study and previously in cell lineages [37] . Interestingly, our results clearly demonstrated that only i.p. administration of RuC had antitumor effects. Oral administration (5 and 10 mg kg −1 ) did not produce such effects. These results suggest the following: (1) RuC may be hydrolyzed by gastric acids, (2) RuC may be poorly absorbed in the intestine, or (3) RuC may be first-pass biotransformed into inactive metabolites in the liver, thus losing its antineoplastic activity. To better understand the behavior of RuC in the gastrointestinal system, pharmacokinetic studies are necessary. The protein binding of Ru(III) complexes, particularly transferrin and albumin [54] , likely impacts its biodistribution, pharmacokinetics, and mechanism of action [55] . Thus, systemic injections may be the best mode of RuC treatment, similar to the cisplatin that is administered intravenously in chemotherapeutic protocols. Considering the suppression of tumor growth by 89% that was induced by 10 mg kg −1 RuC, which was similar to the 91% suppression that was exerted by 2 mg kg −1 cisplatin, we investigated several parameters of the antineoplastic mechanism of action of RuC. We investigated the effects of RuC on protein genes that are related to cell apoptosis in tumor tissue. RuC did not alter the gene expression of key apoptosis-related genes, namely p53, Bax, Bcl-2, and caspase 3 (Fig. 3) , suggesting that apoptosis may not be involved in its antitumor activity against Walker-256 carcinoma. An in vitro experiment with RuC also reported the absence of caspase-3 cleavage in HCT116 p53 +/+ cells, indicating that apoptosis is not the pathway by which RuC promotes cell death [37] . Tumor histology corroborated these results (Fig. 6B,C) , in which extensive areas of necrosis were observed, with no evidence of apoptosis. These results were clearly different for cisplatin, which induced the expression of the pro-apoptotic genes p53, Bax, and caspase 3, which is consistent with previous studies [56, 57] and the histological features of apoptosis in tumors (Fig. 6D) .
Considering the important modulation of oxidative stress in carcinogenesis, we performed assays to evaluate the antioxidant capacity of RuC. RuC prevented the oxidation of DPPH (Fig. 4) , corroborating a previous study of Mohanraj et al. [58] that reported strong radicalscavenging properties of Ru(II) complexes. This activity was also confirmed locally in the tumor in vivo and systemically in kidney and liver tissues (Fig. 5) . The modulation of oxidative stress in tumors may be related to the antitumor effect of RuC in rats, although this compound did not alter the gene expression of Nrf2 and Cat compared with the control group. These results may indicate that the modulation of oxidative stress by RuC does not occur at the genetic level but rather occurs posttranscriptionally and is related to the regulation of enzymatic activity (e.g., SOD and Cat) . The non-influence of regulation of Nrf2 expression by RuC is interesting because recent studies reported a contradictory role for this factor in cancer, which can suppress or promote oncogenesis [59, 60] . Previous studies found evidence that the transient activation of Nrf2 by inducing factors plays a protective role against cancer initiation in normal cells [59] . However, the upregulation of Nrf2 can lead to the activation of cytoprotective genes, thus helping malignant cells withstand high levels of ROS and avoid apoptosis, eventually making them resistant to conventional anticancer therapy [60] .
Reactive oxygen species play different roles in tumors than in healthy tissue because of variations in pH, hypoxia, and an increase in transferrin carriers in the tumor microenvironment. These factors can modulate the redox state and bioavailability of ruthenium in target tissue [61] . The reduction of Ru is facilitated by the presence of reducing conditions, such as hypoxia and GSH; both of these factors were influenced by RuC in Walker-256 cells. RuC treatment significantly increased GSH levels in tumor tissue (Fig. 5J) . Tumors rapidly utilize oxygen and other nutrients, and the development of new blood vessels (i.e., angiogenesis) often fails to keep pace with tumor growth; therefore, there is usually lower O 2 content in tumor cells [61] [62] [63] . RuC apparently promotes inhibition of the respiratory chain, which could lead to more pronounced hypoxia (Fig. 7) . Consequently, tumor cells Significant difference from control and cisplatin groups, respectively (one, two, and three symbols refer to p < 0.05, p < 0.01, and p < 0.001, respectively).
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Free Radical Biology and Medicine 110 (2017) [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] would depend more on glycolysis for energy and may generate excess lactic acid, which lowers pH in the tumor microenvironment. Lactic acid, as well as ascorbic acid, leads Ru(II) to maintain a redox state, thus promoting longer cytotoxic actions [64] [65] [66] . The presence of Walker-256 tumors also creates systemic oxidative conditions [67] , with metabolic damage in several organs. In addition to the tumor, the modulation of oxidative stress by RuC also occurred systemically, demonstrated by oxidative stress that was observed in kidney and liver tissues (Fig. 5) . RuC treatment improved several parameters, such as GSH, GST, and LPO in both kidney and liver tissue and Cat in kidney. These results may be related to the low toxicity of RuC in tumor-bearing (Figs. 1 and 2) and healthy (Fig. 8 ) rats compared with animals that were treated with cisplatin. In the present study, the animals that received cisplatin presented considerable body weight loss, which is consistent with previous studies. High-dose cisplatin (20 mg kg −1 , i.p.) also caused body weight loss, functional and structural alterations of the kidney and liver (i.e., renohepatic toxicity), and mortality [68] . In the present study, Walker-256 tumor-bearing rats that were treated with low-dose cisplatin (2 mg kg −1
, i.p.) presented a decrease in kidney weight, increase in plasma creatinine and urea levels, and lympho-, mono-, and granulocytopenia. Renal lesions were also observed in tumor-free rats that were treated with cisplatin, reflected by an increase in organ weight, tumefaction of the tubular epithelium, pycnosis, and cariorexis. These lesions represent acute and sublethal alterations, characterized by cell edema and changes in the cytoplasm/nucleus ratio. Macroscopically, these lesions were reflected by increases in organ weight and pallor, depending of the degree of cell tumefaction and vascular compression. Our findings corroborate the nephrotoxic effect of cisplatin in tubular cells by necrosis or apoptosis [69] . The loss of plasma membrane integrity and cytosolic edema are early indications of necrosis, whereas the retraction and loss of cell adhesion are features of apoptosis [70] . Additionally, high-dose cisplatin (10 mg kg −1 , i.p.) resulted in mortality in an entire group of Walker-256 tumor-bearing rats within a few days (data not shown).
Altogether, these results demonstrate the systemic toxicity, mainly nephrotoxicity, of cisplatin in rats. Nephrotoxicity is a well-known adverse effect of this drug [68, 71, 72] , which involves increases in oxidative stress, inflammation, and apoptosis and activation of the mitogen-activated protein kinase pathway [73] . Cisplatin elicits oxidative stress in mitochondria in the proximal tubule and endothelial cells, followed by the generation of a secondary wave of reactive oxygen/nitrogen species, the deterioration of mitochondrial structure and function, and renal damage [74] . The present study showed that cisplatin caused renal oxidative damage, manifested by an increase in LPO levels and depletion of the antioxidant molecules GSH, SOD, and Cat in the kidneys compared with the baseline group (Fig. 5) . As cisplatin accumulated in kidney tissue, it covalently bound with the proteins that in turn impacted antioxidant enzymes [75] . Consequently, ), i.p., for 13 days at 3 day intervals. (F) Representative section of the kidney after cisplatin treatment (hematoxylin and eosin staining). Black circles indicate discrete to moderate tumefaction of the tubular epithelium. The data are expressed as mean ± SEM and were analyzed by one-way ANOVA followed by the Bonferroni test. **p < 0.01, ***p < 0.001, significant difference from control group; ## p < 0.01, ### p < 0.001, significant difference from cisplatin group.
tissue damage occurred, and renal markers (i.e., creatinine and urea) were released into the circulatory system. RuC at a dose that exerted antitumor effects (10 mg kg −1
, i.p.) did not induce these adverse effects, which may be attributable to the antioxidant, antiproliferative, and antitumor features of this ruthenium complex [76, 77] . Rats that were treated with RuC presented baseline values of creatinine, urea, AST, ALT, AP, lymphocytes, monocytes, and granulocytes and no changes in body or organ weight. Therefore, our results demonstrate the antineoplastic and non-cytotoxic effects of RuC for the treatment of solid tumors. These features are desirable for the treatment of cancer patients with cachexia, a syndrome that decreases quality of life and increases mortality [78] .
In conclusion, the present results suggest that RuC exerts antitumor activity by modulating oxidative stress, impairing oxidative phosphorylation, and thus promoting Walker-256 cells death, with no systemic toxicity in rats under the present conditions. These effects of RuC make it a promising anticancer drug that should be evaluated in further pharmacokinetic and pharmacodynamic studies and possibly clinical trials.
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